Revealing Angiopep-2/LRP1 Molecular Interaction for Optimal Delivery to Glioblastoma (GBM)
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Revealing Angiopep-2/LRP1 Molecular Interaction for Optimal Delivery to Glioblastoma (GBM)
Authors
Keywords
-
Journal
MOLECULES
Volume 27, Issue 19, Pages 6696
Publisher
MDPI AG
Online
2022-10-10
DOI
10.3390/molecules27196696
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Theranostic Design of Angiopep-2 Conjugated Hyaluronic Acid Nanoparticles (Thera-ANG-cHANPs) for Dual Targeting and Boosted Imaging of Glioma Cells
- (2021) Angela Costagliola di Polidoro et al. Cancers
- ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases
- (2020) Priya Kumthekar et al. CLINICAL CANCER RESEARCH
- Hybrid magnetic nanovectors promote selective glioblastoma cell death through a combined effect of lysosomal membrane permeabilization and chemotherapy
- (2020) Carlotta Pucci et al. ACS Applied Materials & Interfaces
- In-silico analysis of ligand-receptor binding patterns of α-MMC, TCS and MAP30 protein to LRP1 receptor
- (2020) Bin Liu et al. JOURNAL OF MOLECULAR GRAPHICS & MODELLING
- Angiopep-2/IP10-EGFRvIIIscFv modified nanoparticles and CTL synergistically inhibit malignant glioblastoma
- (2018) Xuan Wang et al. Scientific Reports
- PEP-FOLD3: fasterde novostructure prediction for linear peptides in solution and in complex
- (2016) Alexis Lamiable et al. NUCLEIC ACIDS RESEARCH
- The role of the low-density lipoprotein receptor–related protein 1 (LRP-1) in regulating blood-brain barrier integrity
- (2016) Yahui Zhao et al. REVIEWS IN THE NEUROSCIENCES
- Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma
- (2016) Ying Li et al. Oncotarget
- LRP-1-mediated intracellular antibody delivery to the Central Nervous System
- (2015) Xiaohe Tian et al. Scientific Reports
- Current approaches to enhance CNS delivery of drugs across the brain barriers
- (2014) Cui-Tao Lu et al. International Journal of Nanomedicine
- What are lipoproteins doing in the brain?
- (2013) Hong Wang et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles
- (2012) Hongliang Xin et al. BIOMATERIALS
- Molecular Docking: A Powerful Approach for Structure-Based Drug Discovery
- (2012) Xuan-Yu Meng et al. Current Computer-Aided Drug Design
- The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(ɛ-caprolactone) nanoparticles
- (2011) Hongliang Xin et al. BIOMATERIALS
- In silico predictions of 3D structures of linear and cyclic peptides with natural and non-proteinogenic residues
- (2011) Jérôme Beaufays et al. JOURNAL OF PEPTIDE SCIENCE
- Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain
- (2010) Inge van Rooy et al. JOURNAL OF CONTROLLED RELEASE
- Structure of the Minimal Interface Between ApoE and LRP
- (2010) Miklos Guttman et al. JOURNAL OF MOLECULAR BIOLOGY
- Transport characteristics of a novel peptide platform for CNS therapeutics
- (2009) Yanick Bertrand et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Uptake of ANG1005, A Novel Paclitaxel Derivative, Through the Blood-Brain Barrier into Brain and Experimental Brain Metastases of Breast Cancer
- (2009) Fancy C. Thomas et al. PHARMACEUTICAL RESEARCH
- Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2
- (2008) A Régina et al. BRITISH JOURNAL OF PHARMACOLOGY
- 425 POSTER ANG1005: Preliminary clinical safety and tolerability in patients with recurrent malignant glioma
- (2008) J.P. Castaigne et al. EJC SUPPLEMENTS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started